Biologics - Articles and news items

Why biosimilars are changing the pharmaceutical industry

Blog, Z Homepage promo / 26 May 2017 / Ho-ung Kim, Head of Strategy and Operations Division for Celltrion Healthcare

We caught up with Celltrion Healthcare’s Ho-ung Kim to find out how biosimilars cut costs, increase access to medicine and are ultimately changing the industry…

bioreactors

Bioreactors and Fermenters market to reach US$ 4461 million by 2024

Industry news / 11 May 2017 / Niamh Marriott, Junior Editor

The global Bioreactors and Fermenters Market features a largely consolidated vendor landscape and a low to moderate level of competition, says a new report

Digital issue #2 in-depth focus mass spectrometry

Mass Spectrometry In-Depth Focus 2017

Issue 2 2017, Supplements, Z Homepage promo / 13 April 2017 / European Pharmaceutical Review

In this Mass Spectrometry In-Depth Focus: Mass spectrometry in the development of protein biologics; and GC-MS applications in pharmaceuticals analysis…

FDA approves IDE study for bone graft substitute, Cerament G

Industry news / 10 August 2016 / Niamh Louise Marriott, Digital Content Producer

Bonesupport’s Fortify study will evaluate the safety and efficacy of Cerament G as part of surgical repair of open diaphyseal tibial fractures. The trial will enrol up to 230 patients at up to 30 centres globally, with the aim of having at least 50% of the study data coming from US subjects…

Celltrion to develop assay for evidence-based decision-making in anti-TNF treatment

Industry news / 5 July 2016 / Victoria White, Digital Content Producer

Celltrion is to develop laboratory tests that will enable physicians to identify when patients on an anti-TNF drug require a change of dose…

Pfizer breaks ground on new biologics manufacturing facility

Industry news / 17 June 2016 / Victoria White, Digital Content Producer

Pfizer will invest more than $200 million in the development of the state-of-the-art facility that will enable the production of high-quality, complex biologics…

Sanofi makes huge investment in biologics

Sanofi makes huge investment in the future of biologics

Industry news / 19 April 2016 / Mandy Parrett, Editorial Assistant

Sanofi has announced plans to invest €300 million to expand its manufacturing and commercial capabilities at its site in Geel, Belgium.

Whitepaper - Chimera Biotec - April 2016

Whitepaper: Bioanalytical support in the development of biologics

Whitepapers, Z Homepage promo / 1 April 2016 / Chimera Biotec

In this publication Imperacer® case studies demonstrate the advantage of broad assay range combined with excellent sensitivity for several Biologics on their way from R&D to clinics…

Integrated, predictive and collaborative workflows in biologics discovery

Webinars / 23 March 2016 / Dassault Systèmes BIOVIA & GlaxoSmithKline

As well as delving into secure data sharing, the speakers from BIOVIA and GSK will discuss implementing the BIOVIA Biological Registration solution. The speakers will highlight the importance of effective IP protection and improved decision-making through an integrated and collaborative platform…

Tecan simplifies large molecule bioanalysis

Tecan simplifies large molecule bioanalysis

Supplier news / 2 February 2016 / Tecan

Tecan has launched a fully automated affinity purification solution for the extraction of large biomolecules, such as proteins, antibodies and antibody-drug conjugates…

Subvisible particle sizing and counting

Meeting biopharmaceutical analytical requirements for subvisible particle sizing and counting

Biologics, Issue 5 2015 / 22 October 2015 / John Carpenter, University of Colorado / Amber Haynes, Fradkin KBI Biopharma / Christina Vessely, Biologics Consulting Group Inc.

Quantifying and sizing subvisible particles in biopharmaceutical products are crucial aspects of formulation development, stability studies, process development, product release and extended characterisation of the final drug product. The particles, which may consist of aggregated proteins, and/or components shed from process materials or container closure systems, can directly impact on the efficacy and immunogenicity of a drug product. Also, they often act as nucleation sites for further protein aggregation and/or lead to the development of larger particles by agglomeration. Measuring the size and concentration of subvisible particles within a formulation is an essential precursor to their effective control, and of growing importance as the industry works towards ‘zero defect’ and ‘essentially particle-free’ products. In this article we consider requirements for subvisible particle measurement within the context of current regulatory expectations, and more broadly, review the technology available to meet them…

Record Attendance for Cambridge Healthtech Institute's Seventh Annual PEGS Europe Summit

Record attendance for Cambridge Healthtech Institute’s Seventh Annual PEGS Europe Summit

Supplier news / 16 October 2015 / CHI

Largest European Event for Biologics Returns to Lisbon from 2-6 November…

  • Page 1 of 2
  • 1
  • 2
  • >

 

The deadline for submissions to the EPR Awards is 9 June 2017! Entry is FREE, so don't delay...
+